Clinical Trials Sponsored by UCB Belgium

Total 1389 results

UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (BE OPTIMAL)

Psoriatic Arthritis

United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Spain, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

Healthy Study Participants

United Kingdom
UCB Biopharma SRL

Completed

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
UCB Biopharma SRL

No longer available

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
UCB Biopharma SRL

Completed

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

Healthy Study Participants

Japan
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom
UCB Biopharma SRL

Completed

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Healthy Study Participants

United States, Germany
UCB Biopharma SRL

Completed

A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

Belgium, Germany, Spain, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
UCB Biopharma SRL

Active, not recruiting

A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment

Epilepsy

Georgia, Hungary, Moldova, Republic of, Romania, Taiwan, Ukraine
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy

Epilepsy | Partial Seizures With or Without Secondary Generalization

China, Japan, Malaysia, Philippines, Singapore, Taiwan, Thailand
UCB Biopharma SRL

Completed

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Poland, Russian Federation, Serbia, Spain, Taiwan, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Canada
UCB Biopharma S.P.R.L.

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (MyCIDPchoice)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

United States, Belgium, Denmark, France, Germany, Netherlands, Spain, United Kingdom
UCB Biopharma SRL

Available

Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy

Epilepsy
UCB Biopharma SRL

Active, not recruiting

A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures

Epilepsy

United States, Hungary, Italy, Japan, Mexico, Poland, Spain
UCB Biopharma SRL

Completed

A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)

Parkinson's Disease

Netherlands, United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis (BE AGILE)

Ankylosing Spondylitis

United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine
UCB Biopharma SRL

Completed

A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

Parkinson's Disease | Healthy Study Participants

United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects

Healthy Participants

China
UCB Biopharma S.P.R.L.

Terminated

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

Epilepsy

United States, Australia, Hungary, Israel, Poland, Ukraine, Spain, Canada, Germany, New Zealand
UCB Biopharma SRL

Completed

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis (BE ABLE 2)

Chronic Plaque Psoriasis

United States, Canada, Czechia, Hungary, Japan, Poland
UCB Biopharma SRL

Completed

A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

Epilepsy

United States
UCB Biopharma SRL

Terminated

An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

Highly Drug-resistant Focal Epilepsy

Belgium, Bulgaria, Germany, Hungary, Netherlands, Spain
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Moderate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Japan
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants

Healthy-volunteers

United Kingdom
UCB Biopharma S.P.R.L.

Terminated

A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

Impaired Hepatic Function | Healthy Study Participants

United States
UCB Biopharma SRL

Terminated

A Study to Test the Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants

Healthy Female Participants

United Kingdom
UCB Biopharma S.P.R.L.

Terminated

A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants

Healthy Study Participants

United Kingdom
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

Epilepsy | Partial Seizures With or Without Secondary Generalization

Japan
UCB Biopharma SRL

Completed

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU (C-VIEW)

Axial Spondyloarthritis (axSpA) | Anterior Uveitis (AU)

Czechia, Germany, Netherlands, Poland, Spain
UCB Pharma SA

Completed

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (NexT)

Rheumatoid Arthritis

Germany
UCB Biopharma S.P.R.L.

Completed

A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

Epilepsy

Bulgaria, Netherlands
UCB Biopharma S.P.R.L.

Completed

A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers

Healthy Volunteers

United Kingdom
UCB Biopharma S.P.R.L.

Completed

Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

Parkinson´s Disease

United States
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects

Healthy Male Volunteers

Germany
UCB Pharma SA

Completed

Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.

Epilepsy, Tonic-clonic

Poland, Sweden, Hungary, Czechia
UCB BIOSCIENCES GmbH

Completed

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy (BRIGHT)

Idiopathic Parkinson's Disease

United States, Austria, Hungary, Poland, Slovakia, Slovenia, Spain
UCB Pharma SA

Completed

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (PRECiSE 4)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine
UCB Pharma SA

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (C-early)

Rheumatoid Arthritis

Germany, United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, Czechia, France, Hungary, Ireland, Italy, Mexico, Monaco, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom
UCB BIOSCIENCES, Inc.

Completed

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

Partial Epilepsies | Partial Onset Seizures

United States
UCB BIOSCIENCES, Inc.

Completed

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Epilepsy

United States
UCB Pharma SA

Completed

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Epilepsy

United States, France, Germany, Spain
UCB BIOSCIENCES, Inc.

Completed

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB Biopharma S.P.R.L.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects

Healthy Japanese and Caucasian Subjects

United Kingdom
UCB Pharma SA

Completed

Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures

Epilepsy | Partial Seizures

China
UCB Biopharma S.P.R.L.

Completed

A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects

Healthy Male Volunteers

China
UCB Biopharma S.P.R.L.

Completed

A Study to Demonstrate the Bioequivalence of Lacosamide Tablets and Dry Syrup in Healthy Male Japanese Subjects

Healthy Volunteers

United Kingdom
UCB Pharma GmbH

Completed

Observation of Treatment With Certolizumab Pegol in Daily Practice (FasT)

Rheumatoid Arthritis

Germany
UCB Pharma SA

Completed

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

Epilepsy

France, United States, Mexico, Turkey, Belgium, Germany

3

Subscribe